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Abstract
Background: Intermittent preventive treatment (IPT) is a promising intervention for malaria
control, although there are concerns about its impact on drug resistance.
Methods: The key model inputs are age-specific values for a) baseline anti-malarial dosing rate, b)
parasite prevalence, and c) proportion of those treated with anti-malarials (outside IPT) who are
infected. These are used to estimate the immediate effect of IPT on the genetic coefficient of
selection (s). The scenarios modelled were year round IPT to infants in rural southern Tanzania,
and three doses at monthly intervals of seasonal IPT in Senegal.
Results: In the simulated Tanzanian setting, the model suggests a high selection pressure for drug
resistance, but that IPTi would only increase this by a small amount (4.4%). The percent change in
s is larger if parasites are more concentrated in infants, or if baseline drug dosing is less common
or less specific. If children aged up to five years are included in the Tanzanian scenario then the
predicted increase in s rises to 31%. The Senegalese seasonal IPT scenario, in children up to five
years, results in a predicted increase in s of 16%.
Conclusion: There is a risk that the useful life of drugs will be shortened if IPT is implemented
over a wide childhood age range. On the other hand, IPT delivered only to infants is unlikely to
appreciably shorten the useful life of the drug used.
Background
Intermittent preventive treatment (IPT) for malaria is the
administration of a therapeutic course of an anti-malarial
to people who are at risk, regardless of their current infec-
tion status[1].
Trials in African locations of intermittent preventive treat-
ment in infants (IPTi) against clinical malaria have
yielded estimates of efficacy in the range 20–60% [2-5].
However, there are concerns that IPT could foster drug
resistance [6-8], repeating the history of previous control
methods which administered anti-malarials to people
who were not malaria cases[1]. Selection pressure for
resistance depends not only on the drug dosing rate, but
also on the infection status of the recipients[9].
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Some drug resistance models may meet their objectives
without explicitly including age structure[10,11]. How-
ever, the use of IPT in children is, by definition, depend-
ent on age. Moreover, both drug dosing rate and infection
status are likely to vary significantly in children according
to their age and immune status. These considerations led
us to devise a simple model for the genetic coefficient of
selection (s) for a drug resistance associated gene, or
linked set of genes.
Methods
Model definition
The spread of a drug-resistant genotype can be expressed
in terms of the selection coefficient s, which is the relative
difference in reproductive success. Following Brown and
Rothery [12], but for Plasmodium rather than a diploid
organism, the (relative) frequency of the resistant geno-
type is expected to increase logistically with parameter
s[13]. Logistic growth is approximately exponential
growth at small relative frequencies, then approximately
linear at relative frequencies around 50%, and finally
asymptotically approaches 100%. The selection coeffi-
cient s is modelled as a function of: age-dependent para-
site prevalence p(a); prevalence π(a) of a history of taking
anti-malarials in the previous d days; and positive predic-
tive value ψ(a) of anti-malarial treatment, i.e. the propor-
tion of those treated with anti-malarials (outside of IPT)
who were, in fact, infected. In the general population, the
dosing rate is λ(a) = -log(1-π(a))/d, and in parasite posi-
tive people it is λ+(a) = -ψ(a) log(1-π(a))/(p(a)d).
The following form was chosen to represent parasite prev-
alence:
This function p(a) increases from zero at age a = 0 to reach
its maximum value at age a = log(B/(A(1+C)))/(B-A), with
an asymptote at large a of CA/(A-B). For the drug history
π(a), and positive predictive value ψ(a), logistic functions
are used, with the form:
where U and L are the upper and lower asymptotes respec-
tively, ã = -α/β is the age at which the midpoint of U and
L is attained, and β measures the steepness of the transi-
tion. Note that gene frequency is expected to follow a
logistic function of time on the basis of population
genetic theory[12], whereas logistic functions of age are
used for drug history (π) and positive predictive value (ψ)
because they approximate empirically the patterns seen in
the data sources used (see below, subsection 'Parameter
values'). The implementation of IPT, at a given rate of
doses per year, is included by adding this rate to the pre-
IPT dosing rates. This completes the specification of the
dosing rates λ(a) and λ+(a).
The fitness of an inoculated parasite – or the number of
next-generation infections to which it gives rise – is, by
default, assumed to be proportional to the duration D of
infection in the host. However, in sensitivity analysis, the
infectivity was allowed to decrease, exponentially, at vari-
ous rates, over the duration of the infection. In the
absence of drug, a default value of 3 months is used for
D[9,14]. In the presence of drug, it is necessary to work
out the expected duration D' <D of a sensitive infection.
This is done as the probability-weighted sum over three
cases. First, the drug may be present at an effective level at
the time of parasite inoculation, with probability 1 - exp(-
λ(a)d'), where d' is the number of days for which the drug
retains its killing effect (default value 14 days, represent-
ing sulfadoxine-pyrimethamine or SP). In this case the
duration of the infection is zero. Second, the infection
may persist, unaffected by drug ingestion, for its natural
duration  D, with probability 1 - exp(-λ(a)d') exp(-
λ+(a)D). Third, the drug is not present on inoculation, but
is taken before the infection ends naturally. The expected
value of infection duration is then the integral
. Adding the three expected values yields the expected
duration D' as a function of age:
The total fitness of a parasite genotype is proportional to
the number of next-generation parasites, integrated over
the whole human age range. The contribution of small age
interval,  a  to  a+δa, is proportional to: i) D'(a)
(equation3); ii) the number of people in the interval; iii)
the proportion of them who are parasitaemic, ie p(a)
(equation1); and iv) the width of the interval δa. Assum-
ing Type II mortality, ie a population pyramid which
reduces exponentially with age, the number of people in
the age interval is proportional to exp(-a/ ), where   is
the mean age in years (default 15 years). It was assumed
that no malaria infections, and no IPT dosing, occur
below a minimum age a0, default value 2 months. There-
fore the fitness is proportional to  .
This integral is evaluated numerically. The reproductive
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success of resistant parasites is calculated by setting the
dosing rate to zero, and s is obtained as one minus the
ratio of fitness of sensitive to resistant parasites.
In areas of seasonal transmission, a higher maximum age
of IPT may be used, with dosing concentrated in the trans-
mission season. Here, s was estimated via a weighted sum
of the fitness in each season.
In this simple model parasite prevalence appears only as
an input, not an output. So IPT does not feed back into
prevalence, and the effects on selection pressure are those
immediately following the introduction of IPT.
Parameter values
The key input parameters were chosen for rural southern
Tanzania. Unpublished data from surveys by Armstrong
Schellenberg and colleagues[15] estimated that the 14-
day history of anti-malarial dosing π (a) decreased from
approximately 10% in young children to 5% in adults.
Parasite prevalence p(a) was chosen to approximately
reflect the situation in the same location, and was
assumed to peak at 50% at age 5 years, decreasing to 10%
in adults. The positive predictive value of treatment ψ (a)
was assumed to decrease from 60% in children to 20% in
adults[16]. The following values were used: β = -1, and ã
= 10 years for π(a), 5 years for ψ(a). Default values for
p(a), π(a) and ψ(a) are shown in Figure 1.
Parameters for the seasonal IPT scenario, in children up to
five years, were chosen to reflect Niakhar, Senegal. Peak
parasite prevalence was set at age 7 years, and was 90% in
the three month high transmission, otherwise 40%. The
asymptotes of π(a) at low and high ages were 33% and
12% respectively in the high transmission season; other-
wise 5% and 2%. The corresponding values for ψ(a) were
95% and 85% in the transmission season, otherwise 50%
and 20%. Other parameters were unchanged.
Results
In the simulated Tanzanian setting, the selection coeffi-
cient for resistant parasites in the absence of IPT is esti-
mated at 0.267, and in the presence of IPTi is 0.279, an
increase of 4.4%. So resistant parasites are expected to
yield, on average, about 27% more offspring than sensi-
tive ones, but IPTi makes a negligible impact on this.
Sensitivity analysis of the default parameters is shown in
Figure 2, with each panel showing contours of the esti-
mated percent change in the selection coefficient (s) when
a selected pair of parameters is varied, with the ❍ symbol
shows the default values. Since the default values give a
change in s of 4.4%, the ❍ symbol lies between the con-
tours of 4% and 5% (or between 4 and 8%, in panel b)).
Panel a) shows the strongest predicted effect on s occurs
when peak parasitaemia prevalence is high, and occurs in
younger children (i.e. towards the left and top of the
graph). Panel b) show the percent change in s would, as
expected, be greater if the background dosing rate were
less. Panel c) shows that the effect on s is greater if the pos-
itive predictive value of the non-IPT dosings is less. This
can be understood as follows. If the non-IPT dosings are
being directed less efficiently to those infected, then the
impact on parasites is less, but, when IPT is introduced,
the percent change in s is greater. Paneld) shows that the
percent change in s is slightly lower for drugs which are
effective for longer, probably because of greater overlap of
IPT and non-IPT dosings. Panel d) also shows that the
effect on s of the rate of decrease of transmissibility is very
small. The percent change in s is also slightly larger if the
natural duration of infection is shorter. Within the plausi-
ble ranges examined, the background dosing rate is the
most important determinant of the predicted impact of
IPT on selection pressure, leading to increases in s of 16%
or more (panel b)), while varying the other parameters
leads to changes in s of no more than about 8%. Changing
the minimum age a0 – below which no malaria infections,
and no IPT dosing, was assumed to occur – from 2
months to 1 or 0.5 months made negligible difference to
the results. If children aged up to five years are included
then the predicted increase in s is much greater: 31% (note
that is a percent chance in s, not the value of s itself). The
interpretation depends on whether selection is in the ear-
lier, approximately exponential, phase or the later,
Model inputs Figure 1
Model inputs. Default prevalence curves, illustrating the 
default parameter values for the proportion of people slide 
positive (p, solid line), the proportion with a 14 day history 
of taking anti-malarials (π, dashed line), and the positive pre-
dictive value of (ψ, dotted line).
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approximately linear phase of the logistic curve[17]. In
the exponential phase, the gene frequency's doubling time
is reduced by about 31%. In the linear phase, the time for
the frequency to increase any given number of percentage
points is reduced by about 31%. The exponential phase
occurs at low gene frequency, so in absolute terms, the
resistant genotype spreads faster in the linear phase. The
Senegalese seasonal IPT scenario results in a predicted
increase in s of 16%.
Discussion
The model is intended to yield order of magnitude esti-
mates for different policies, rather than precise values. It
makes several simplifying assumptions, but should be
much more realistic than using plain drug mass as a meas-
ure of selection pressure. It is also limited in that it looks
at the immediate impact of IPT on selection pressure, but
does not incorporate feedback effects of IPT on parasite
prevalence, and hence the tendency of IPT to reduce non-
IPT dosings below their baseline value. However, where
the impact of selection pressure is small, then these feed-
back effects would also be small. The model is applicable
to combinations such as sulfadoxine-pyrimethamine
(Fansidar) or chlorproguanil-dapsone (Lapdap) by using
the gene frequency of the set of mutations needed to con-
fer resistance. The half-lives of the single drugs amodi-
aquine (7–21 days[18]) and mefloquine (14–21
days[19]) are in the range of the sensitivity analysis shown
in Figure 2d, which shows their expected results are simi-
lar to those of sulfadoxine-pyrimethamine (bearing in
Sensitivity analysis of main parameters Figure 2
Sensitivity analysis of main parameters. Each panel shows contours of the percent change in selection coefficient s, as a 
function of two parameters. The default parameter values (Tanzanian setting), and predicted change in s, are shown by ❍ in 
each panel. Parts of panels b) and c) are blank because of the assumption that the drug history, and positive predictive value of 
treatment, would be higher in young children than adults.
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mind the assumption that the same drug is used for IPT as
for non-IPT therapy). However, when mutations in multi-
ple unlinked genes are needed for resistance, breakdown
of their association by recombination will undermine the
impact of selection on the spread of resistance. Combina-
tion therapy would also be advantageous if the required
set of mutations was initially absent in the population, so
that selection could not start to act.
Most of these findings are in accordance with those of
Prudhomme O'Meara et al[20]: in particular, that the
effect of IPTi on selection pressure is likely to be relatively
small when treatment is already frequent. Also, their pre-
diction that the spread of fully resistant parasites is likely
to be greater in high transmission areas corresponds to
that made in the current paper, that the spread will be
greater when parasitaemia is more clustered in younger
children (since this happens in high transmission
areas[21]). Although generally less sophisticated, the cur-
rent approach does include some features not present in
their model: in particular, presumptive treatment of unin-
fected people outside IPT. We also considered IPT in chil-
dren older than infants.
The baseline selection coefficient (s) estimated for the
Tanzanian setting (27%) is towards the high end of the
range of 3–33% estimated by Anderson[22] from previ-
ously published data on gene frequencies. Tanzania
intends to change first line drug treatment to artemether-
lumefantrine (CoArtem)[23]. In that situation, the cur-
rent model would assume that non-IPT treatments would
exert no selection pressure on the genotypes associated
with resistance to the IPT drug (SP). After introduction,
the predicted selection coefficient is 1.1% (approximately
equal to the change in selection coefficients when adding
IPTi to a background of SP treatment), suggesting that IPTi
has little impact on selection pressure in this setting.
Prudhomme O'Meara et al[20] concluded that 'Drugs to
which little or no resistance exists are not advisable for IPT
in high-transmission areas' because this 'could accelerate
the appearance of partial resistance, which could be fol-
lowed by explosive spread of full resistance'. This assumes
that a stepwise accumulation of resistance-associated
mutations is the dominant mechanism of the evolution of
resistance. However, recent empirical studies have dem-
onstrated that the introduction and spread of alleles of
geographically distant origin has been particularly impor-
tant in the development of resistance to antifolates[24].
This would suggest different advice: that implementation
of IPT with a combination of drugs not currently used in
the intervention area is most likely to maximize both mor-
bidity reduction and drug lifespan. However, given that
'There is no consensus on how IPT works'[25], further
empirical and theoretical work is needed to minimize the
impact of resistance on its implementation.
Conclusion
There are dangers of shortening the useful life of drugs if
IPT is implemented over a wide childhood age range. On
the other hand, IPT delivered only to infants is unlikely to
appreciably shorten the useful life of the drug used.
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